Literature DB >> 1716414

Tumor proliferative fraction in solid malignant neoplasms. A comparative study of Ki-67 immunostaining and flow cytometric determinations.

A A Sahin1, J Y Ro, A K el-Naggar, P L Wilson, K Teague, M Blick, A G Ayala.   

Abstract

Tumor proliferative fraction (TPF) has been shown to correlate with prognosis in some malignancies. A method for its determination that is practical, accurate, and reproducible is still being sought. In this comparative study of techniques, TPF values were determined in mirror-image samples of 126 consecutive solid malignant neoplasms using flow cytometry and immunostaining with Ki-67, a monoclonal antibody that recognizes an unknown nuclear antigen expressed during the entire cell proliferation cycle but not in resting cells. The mean TPF values for all cases were 19.5 +/- 15.6% (percentage of tumor cells stained) by Ki-67 (range, 1-86%) and 15.7 +/- 9.6% (S + G2M) by flow cytometry (range, 3-60%), which correlated significantly at r = 0.53 and P = 0.005. The correlation was less strong in tumors with low S-phase values (less than or equal to 10%, r = 0.28) than in tumors with intermediate and high S-phase values (r = 0.66). Ki-67 staining percentages did not correlate with patient age, sex, or tissue origin of the tumor. Ki-67 staining appears comparable to flow cytometry determination of TPF in solid malignancies with intermediate and high S-phase values. In tumors with low S-phase values, Ki-67 immunostaining shows higher TPF values, which perhaps reflect an increase in the proportion of G1-phase cells or dilutional effect of nonneoplastic cells in the tumors with low proliferative fraction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716414     DOI: 10.1093/ajcp/96.4.512

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  11 in total

1.  Regional differences in breast cancer biomarkers in american Indian and Alaska native women.

Authors:  Judith S Kaur; Robert A Vierkant; Timothy Hobday; Daniel Visscher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03       Impact factor: 4.254

2.  Ki-67 expression in pulmonary tumors.

Authors:  Lucian R Chirieac
Journal:  Transl Lung Cancer Res       Date:  2016-10

3.  A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1.

Authors:  H Kreipe; H J Heidebrecht; S Hansen; W Röhlk; M Kubbies; H H Wacker; M Tiemann; H J Radzun; R Parwaresch
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

4.  A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors.

Authors:  Kabir Mody; Aaron S Mansfield; Lalitha Vemireddy; Peter Nygren; Joachim Gulbo; Mitesh Borad
Journal:  Invest New Drugs       Date:  2018-11-21       Impact factor: 3.850

5.  A comparative study of cell proliferation markers in breast carcinomas.

Authors:  A S Leong; S Vinyuvat; C Suthipintawong; J Milios
Journal:  Clin Mol Pathol       Date:  1995-04

6.  Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer.

Authors:  Yogev Sela; Jinyang Li; Shivahamy Maheswaran; Robert Norgard; Salina Yuan; Maimon Hubbi; Miriam Doepner; Jimmy P Xu; Elaine S Ho; Clementina Mesaros; Colin Sheehan; Grace Croley; Alexander Muir; Ian A Blair; Ophir Shalem; Chi V Dang; Ben Z Stanger
Journal:  Cancer Res       Date:  2022-05-16       Impact factor: 13.312

7.  Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features.

Authors:  P C Huettner; D S Weinberg; J M Lage
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

8.  Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.

Authors:  Sarah F Adams; Douglas A Levine; Mark G Cadungog; Rachel Hammond; Andrea Facciabene; Narciso Olvera; Stephen C Rubin; Jeff Boyd; Phyllis A Gimotty; George Coukos
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

9.  Proliferative activity (ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases.

Authors:  R Jong; A M Davis; M G Mendes; J S Wunder; R S Bell; R Kandel
Journal:  Sarcoma       Date:  2000

10.  Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments.

Authors:  Xiaonan Zhang; Mårten Fryknäs; Emma Hernlund; Walid Fayad; Angelo De Milito; Maria Hägg Olofsson; Vladimir Gogvadze; Long Dang; Sven Påhlman; Leoni A Kunz Schughart; Linda Rickardson; Padraig D'Arcy; Joachim Gullbo; Peter Nygren; Rolf Larsson; Stig Linder
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.